

Special Issue

Radiation Response Biomarkers for Individualised Cancer Treatments

Message from the Guest Editors

It is an important and effective tool in the arsenal to treat numerous solid tumours. Improving the precision of radiotherapy has long been the quest of cancer scientists and clinicians. Biomarkers are essential for predicting and/or monitoring radiation exposure-associated effects. Ever-evolving technologies allow the detection and validation of new and emerging radiation biomarkers, whether genetic, epigenetic, cell-based, cell-free, or present in extracellular vesicles. The aim of this Special Issue is to present an insight into the ongoing state-of-the-art research in the oncology radiation response biomarker field and its applications in the ever-evolving field of personalised medicine. We welcome original scientific manuscripts (both clinical and research-based), reviews reporting novel findings in the field of radiation response, and biomarkers indicative of patient-tailored treatment and monitoring in both in vitro and in vivo systems, with a focus on research in human systems, as well as technical papers on new developments in protocols to study and validate these biomarkers.

Guest Editors

Dr. Christophe Badie


Cancer Mechanisms and Biomarkers Group, Radiation Effects
Department, Public Health England, Centre for Radiation, Chemical and
Environmental Hazards, Chilton, Didcot, Oxon OX11 0RQ, UK

Dr. Eric Andreas Rutten

Cancer Mechanisms and Biomarkers Group, Radiation Effects
Department, Public Health England, Centre for Radiation, Chemical and
Environmental Hazards, Chilton, Didcot, Oxon OX11 0RQ, UK

Deadline for manuscript submissions

closed (10 December 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/46205

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).